PH30756A - X-ray contrast compositions useful in medical imaging. - Google Patents

X-ray contrast compositions useful in medical imaging.

Info

Publication number
PH30756A
PH30756A PH43830A PH43830A PH30756A PH 30756 A PH30756 A PH 30756A PH 43830 A PH43830 A PH 43830A PH 43830 A PH43830 A PH 43830A PH 30756 A PH30756 A PH 30756A
Authority
PH
Philippines
Prior art keywords
ray contrast
medical imaging
blood pool
compositions useful
ray
Prior art date
Application number
PH43830A
Other languages
English (en)
Inventor
Gary G Leverridge
Eugene R Cooper Jr
Shaw Michael
Gregory L Mcintire
Original Assignee
Sterling Wintdrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27095087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH30756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/647,105 external-priority patent/US5145684A/en
Application filed by Sterling Wintdrop Inc filed Critical Sterling Wintdrop Inc
Publication of PH30756A publication Critical patent/PH30756A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH43830A 1991-01-25 1992-01-24 X-ray contrast compositions useful in medical imaging. PH30756A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/647,105 US5145684A (en) 1991-01-25 1991-01-25 Surface modified drug nanoparticles
US81026191A 1991-12-19 1991-12-19

Publications (1)

Publication Number Publication Date
PH30756A true PH30756A (en) 1997-10-17

Family

ID=27095087

Family Applications (1)

Application Number Title Priority Date Filing Date
PH43830A PH30756A (en) 1991-01-25 1992-01-24 X-ray contrast compositions useful in medical imaging.

Country Status (22)

Country Link
US (2) US5318767A (da)
EP (1) EP0498482B1 (da)
JP (1) JPH04317053A (da)
KR (1) KR920014481A (da)
AT (1) ATE184202T1 (da)
AU (1) AU642066B2 (da)
CA (1) CA2059431A1 (da)
DE (1) DE69229925T2 (da)
DK (1) DK0498482T3 (da)
ES (1) ES2139586T3 (da)
FI (1) FI920322A7 (da)
GR (1) GR3032059T3 (da)
HU (1) HU208497B (da)
IE (1) IE920218A1 (da)
IL (1) IL100755A (da)
MX (1) MX9200292A (da)
MY (1) MY109075A (da)
NO (1) NO920333L (da)
NZ (1) NZ241361A (da)
PH (1) PH30756A (da)
RU (1) RU2074002C1 (da)
TW (1) TW199101B (da)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
SE470086B (sv) * 1991-04-23 1993-11-08 Kabi Pharmacia Ab Organspecifik emulsion
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5260478A (en) * 1992-12-08 1993-11-09 Sterling Winthrop Inc. Iodinated aroyloxy carboxamides
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5346688A (en) * 1992-12-16 1994-09-13 Sterling Winthrop Inc. Iodinated wetting agents
US5322679A (en) * 1992-12-16 1994-06-21 Sterling Winthrop Inc. Iodinated aroyloxy esters
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
CA2155947C (en) * 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1999000113A1 (en) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
GB9303992D0 (en) * 1993-02-26 1993-04-14 Nycomed Imaging As Contrast agents
US5310537A (en) * 1993-03-01 1994-05-10 Sterling Winthrop Inc. Compositions of iodoaniline derivatives for visualization of the gastrointestinal tract
US5330740A (en) * 1993-03-01 1994-07-19 Sterling Winthrop Inc. Compositions of iodoaniline derivatives in film-forming materials for visualization of the gastrointestinal tract
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5368837A (en) * 1994-04-14 1994-11-29 Sterling Winthrop Inc. X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative
US5488133A (en) * 1994-03-10 1996-01-30 Eastman Kodak Company Iodinated aroyloxy ketones
US5535746A (en) * 1994-03-29 1996-07-16 Sterling Winthrop Inc. Prefilled syringe for use with power injector
US5513803A (en) * 1994-05-25 1996-05-07 Eastman Kodak Company Continuous media recirculation milling process
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5478705A (en) * 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) * 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
AU2823795A (en) * 1994-06-24 1996-01-19 Nanosystems L.L.C. 2,4,6-triiodo-5-substituted-amino-isophthalate esters useful as x-ray contrast agents for medical diagnostic imaging
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5567410A (en) * 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
AU4867296A (en) * 1995-02-14 1996-09-04 Nanosystems L.L.C. Process of preparing lymphography contrast agents
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
WO1996028414A1 (en) * 1995-03-09 1996-09-19 Nanosystems L.L.C. Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) * 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5603916A (en) * 1995-05-22 1997-02-18 Nano Systems L.L.C. 3 5-bis alkanoyl amino-2 4 6-triiodobenzyl esters
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5662279A (en) * 1995-12-05 1997-09-02 Eastman Kodak Company Process for milling and media separation
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
WO1997030459A1 (en) * 1996-02-14 1997-08-21 Philips Electronics N.V. X-ray examination apparatus with x-ray filter
GB9603547D0 (en) * 1996-02-20 1996-04-17 Nycomed Imaging As Contrast media
PT101919B (pt) * 1996-09-30 2000-01-31 Hovione Sociedade Quimica Sa Um processo para a purificacao de tohexol
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
WO1998048847A1 (en) * 1997-04-25 1998-11-05 Nycomed Imaging As Nanoparticle composition containing iodinated x-ray contrast agent as stabilizer for thermal sterilization
GB9710604D0 (en) * 1997-05-22 1997-07-16 Nycomed Imaging As Contrast media
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE276745T1 (de) * 1998-04-09 2004-10-15 Amersham Health As Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6132044A (en) * 1998-11-20 2000-10-17 Luxottica Leasing S.P.A Filter for a special purpose lens and method of making filter
US6203778B1 (en) 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
RU2155072C1 (ru) * 1999-03-09 2000-08-27 Алтайский государственный медицинский университет Способ непрямой лимфографии внутригрудных лимфатических узлов в эксперименте
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AU5967101A (en) 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US20040235809A1 (en) * 2000-07-27 2004-11-25 Alexander John C Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PL212985B1 (pl) 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
RU2217052C2 (ru) * 2001-06-01 2003-11-27 Драцкий Сергей Иванович Способ определения подвижности почки у детей
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
WO2003000228A2 (en) * 2001-06-22 2003-01-03 Elan Pharma International Ltd. Method for high through put screening using a small scale mill or microfluidics
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60229406D1 (de) * 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1450863A4 (en) * 2001-11-07 2009-01-07 Imcor Pharmaceutical Company PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
ATE539737T1 (de) 2002-04-12 2012-01-15 Alkermes Pharma Ireland Ltd Nanopartikuläre megestrol- formulierungen
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
EP2283864A1 (en) 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US20040054413A1 (en) * 2002-09-16 2004-03-18 Howmedica Osteonics Corp. Radiovisible hydrogel intervertebral disc nucleus
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CA2504916A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ATE514418T1 (de) * 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20040173696A1 (en) * 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US7390505B2 (en) * 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) * 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1622649A2 (en) * 2003-05-06 2006-02-08 Philips Intellectual Property & Standards GmbH Apparatus and method for examining an object by means of elastically scattered x-ray radiation and contrast agent
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
ES2318330T3 (es) * 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
WO2005044234A2 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
WO2005051511A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation 有機化合物微粒子の製造方法
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
WO2006028074A1 (ja) * 2004-09-07 2006-03-16 Mitsubishi Chemical Corporation 微粒子化された物質の製造方法および微粒子化された物質
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070065374A1 (en) * 2005-03-16 2007-03-22 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
MX2007011772A (es) * 2005-03-23 2007-12-05 Elan Pharma Int Ltd Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
EP1866155A2 (en) * 2005-04-05 2007-12-19 Bar-Ilan University New core and core-shell nanoparticles containing iodine for x-ray imaging
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7825087B2 (en) * 2005-04-12 2010-11-02 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
CN101212954A (zh) * 2005-05-10 2008-07-02 伊兰制药国际有限公司 纳米粒氯吡格雷制剂
MX2007014363A (es) * 2005-05-16 2009-04-15 Elan Pharma Int Ltd Composiciones de liberacion controlada y en forma de nanoparticulas que comprenden una cefalosporina.
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2007053197A2 (en) * 2005-06-03 2007-05-10 Elan Pharma International, Limited Nanoparticulate acetaminophen formulations
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
EP1898911A1 (en) * 2005-06-13 2008-03-19 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2008543842A (ja) * 2005-06-14 2008-12-04 バクスター インターナショナル インコーポレイテッド 薬物−薬物相互作用を最小にするための薬学的処方物
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
GB0512666D0 (en) * 2005-06-22 2005-07-27 Univ Loughborough Method for concentrating nanosuspensions
US20090180964A1 (en) * 2005-06-24 2009-07-16 Rao Papineni Transmucosal delivery of optical, spect, multimodal,drug or biological cargo laden nanoparticle(s) in small animals or humans
ATE520396T1 (de) * 2005-06-29 2011-09-15 Dsm Ip Assets Bv Isoflavon-nanoteilchen und ihre verwendung
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
GB0516549D0 (en) * 2005-08-12 2005-09-21 Sulaiman Brian Milling system
US20070104792A1 (en) * 2005-09-13 2007-05-10 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
WO2007035348A2 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US7407647B2 (en) * 2005-12-07 2008-08-05 Cordis Corporation Organic radiographic contrasting agents for medical devices
US20070134163A1 (en) * 2005-12-13 2007-06-14 Zhao Jonathon Z Radiographic contrasting agents and radio-opaque polymeric materials for medical devices
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CN101495096A (zh) * 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
DE102006042729A1 (de) * 2006-09-12 2008-03-27 Siemens Ag Verfahren zum Erzeugen eines Röntgenbildes
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
EP2268265A2 (en) * 2008-03-21 2011-01-05 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US20100092390A1 (en) * 2008-10-09 2010-04-15 President And Fellows Of Harvard College Methods for Making Particles Having Long Spin-Lattice Relaxation Times
KR101130737B1 (ko) * 2008-12-24 2012-03-28 경북대학교 산학협력단 방사성 세포 표지자
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
EP2253306A1 (en) 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
JP6072539B2 (ja) 2009-05-27 2017-02-01 アルカーメス ファーマ アイルランド リミテッド ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
RU2545784C2 (ru) 2009-06-19 2015-04-10 Наноформ Хунгари Лтд. Наноструктурированное основание силденафила, его фармацевтически приемлемые соли и со-кристаллы, их композиции, способ их получения и содержащие их фармацевтические композиции
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
JP6871919B2 (ja) * 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
SG11202101714TA (en) 2018-08-21 2021-03-30 Chevron Usa Inc Catalytic reforming process and system for making aromatic hydrocarbons
WO2020060786A1 (en) 2018-09-17 2020-03-26 Chemence Medical, Inc. Stable compositions composed of a radiopaque agent and cyanoacrylate monomer and applications thereof
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
JP2024505153A (ja) * 2021-01-12 2024-02-05 ボストン サイエンティフィック サイムド,インコーポレイテッド 放射線造影特性を有するヨウ素化合物
CN117280200A (zh) * 2021-05-06 2023-12-22 株式会社理学 X射线造影剂和x射线图像的取得方法
WO2026108771A2 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof
WO2026108769A1 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996433A (en) * 1958-09-11 1961-08-15 Sterling Drug Inc Radiopaque formulations
US3192118A (en) * 1964-04-23 1965-06-29 Fmc Corp Cellulose crystallites radiopaque media
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
JPS51129331A (en) * 1975-04-22 1976-11-10 Salomon & Fils F Device for braking ski after detachment from ski boot
CH615344A5 (en) * 1975-06-16 1980-01-31 Bracco Ind Chimica Spa X-ray contrast medium and process for its preparation
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
GB8900376D0 (en) * 1989-01-09 1989-03-08 Nycomed As Iodinated esters
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
US5019370A (en) * 1989-07-10 1991-05-28 University Of Kentucky Research Foundation Biodegradable, low biological toxicity radiographic contrast medium and method of x-ray imaging
US5075502A (en) * 1989-12-13 1991-12-24 Mallinckrodt, Inc. Nonionic x-ray contrast agents, compositions and methods
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DE69122845T2 (de) * 1990-12-28 1997-02-20 Mitsubishi Electric Corp Kontaktlose IC-Karte
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
NL9100191A (nl) * 1991-02-04 1992-09-01 Philips Nv Werkwijze voor het vervaardigen van een magneetkop en magneetkop vervaardigd volgens de werkwijze.

Also Published As

Publication number Publication date
IE920218A1 (en) 1992-07-29
DE69229925D1 (de) 1999-10-14
US5451393A (en) 1995-09-19
HUT60635A (en) 1992-10-28
JPH04317053A (ja) 1992-11-09
FI920322L (fi) 1992-07-26
NZ241361A (en) 1993-06-25
EP0498482B1 (en) 1999-09-08
ES2139586T3 (es) 2000-02-16
TW199101B (da) 1993-02-01
EP0498482A3 (en) 1993-03-03
DE69229925T2 (de) 2000-02-17
US5318767A (en) 1994-06-07
RU2074002C1 (ru) 1997-02-27
HU9200227D0 (en) 1992-04-28
KR920014481A (ko) 1992-08-25
IL100755A (en) 1995-12-08
FI920322A7 (fi) 1992-07-26
MY109075A (en) 1996-11-30
DK0498482T3 (da) 2000-03-27
ATE184202T1 (de) 1999-09-15
AU642066B2 (en) 1993-10-07
NO920333D0 (no) 1992-01-24
NO920333L (no) 1992-07-27
AU1014592A (en) 1992-07-30
CA2059431A1 (en) 1992-07-26
MX9200292A (es) 1992-10-01
IL100755A0 (en) 1992-09-06
EP0498482A2 (en) 1992-08-12
FI920322A0 (fi) 1992-01-24
HU208497B (en) 1993-11-29
GR3032059T3 (en) 2000-03-31

Similar Documents

Publication Publication Date Title
IL100755A0 (en) X-ray contrast compositions useful in medical imaging
PH29957A (en) Use of tyloxapol as a nano-particle stabilizer and dispersant
MY109875A (en) Novel formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight surfactants.
NO308193B1 (no) Sammensetning som omfatter overflatemodifiserte anticancernanopartikler, fremgangsmÕte for fremstilling av disse samt anvendelse
IL107518A0 (en) Therapeutic and diagnostic compositions comprising purified surface modifiers to prevent particle aggregation during sterilization
EP0951917A3 (en) Particle delivery of particularly a powdered therapeutical agent
ATE150297T1 (de) Oberflaechenmodifizierte nsaid nanopartikeln
HU9200226D0 (en) Active agent particles with modified cover
LTIP609A (en) Multinuclear complexes, contrast media containing them and use
FI925284A7 (fi) Ultraääni- ja röntgenkuvauksessa käytettävissä koostumuksissa ja menetelmissä varjoaineina käyttökelpoiset kapseloidut hiukkaset
Ansell 27. Toxicity of opaque media used in X-ray diagnosis.